// App-Quantinova.ai

5057 : Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Alice Bernard-Tessier

Principal Investigators

  • Tapio Utriainen

  • Natalie Cook

  • Philippe Barthélémy

  • Nada Lallous

  • Martin Gleave

  • Tarja Ikonen

  • Reetta Riikonen

  • Pasi Pohjanjousi

  • Chris Garratt

  • Karim Fizazi

Medical Centers

  • Institut Gustave-Roussy, Villejuif, France

  • Helsinki University Central Hospital Cancer Center, Helsinki, Finland

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Institut de Cancérologie Strasbourg Europe,Strasbourg, France, Strasbourg, France

  • The University of British Columbia, Vancouver, BC, Canada

  • The University of British Columbia, Vancouver, BC, Canada

  • Orion Oyi, Espoo, Finland

  • Orion Corporation Orion Pharma, Turku and Espoo, Finland

  • Orion Corporation Orion Pharma, Turku and Espoo, Finland

  • Orion Pharma, Nottingham, United Kingdom

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

Locations

  • France

  • Finland

  • United Kingdom

  • Canada

Companies

  • Orion Corporation

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Plasma cell-free DNA

Drug/Treatment

  • Fludrocortisone

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Androgen Tear

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03436485

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved